On July 24, Edwards Lifesciences rose 5.57% overnight, trading at $88.49/share. The rally was driven by the company's Q2 earnings release, which exceeded analyst expectations across all key metrics.

Edwards Lifesciences reported Q2 adjusted EPS of $0.78, beating the consensus estimate of $0.74 by 5.41% and representing a 16.42% increase year-over-year. Revenue reached $1.741 billion, surpassing the $1.700 billion estimate, up from $1.53 billion a year earlier. The core TAVR product line delivered $1.26 billion in quarterly sales, growing 11.3% year-over-year and exceeding the $1.23 billion market expectation. Notably, the company raised its full-year TAVR sales growth guidance lower bound from 7% to 8%, while reaffirming full-year adjusted EPS of $2.95 to $3.05. For Q3, management guided adjusted EPS of $0.71 to $0.77 on revenue of $1.63 billion to $1.71 billion. The strong results reflect robust demand for transcatheter heart valve replacement devices amid an under-penetrated global market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)